title: Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial.
abstract: A phase I-II clinical trial was performed involving vaccination with HPV16 E7 peptides of patients suffering from HPV16 positive cervical carcinoma which was refractory to conventional treatment. Patients receiving the vaccine were HLA-A*0201 positive with HPV16 positive cervical carcinoma. The clinical trial was designed as a dose-escalation study, in which successive groups of patients received 100 micrograms, 300 micrograms or 1000 micrograms of each peptide, respectively. The vaccine consisted of two HPV16 E7 peptides and one helper peptide emulsified in Montanide ISA 51 adjuvant. 19 patients were included in the study, no adverse side-effects were observed. 2 patients showed stable disease for 1 year after vaccination; 15 patients showed progressive disease of whom 1 died during the vaccination treatment due to progressive disease; and 2 patients showed tumour-regression after chemotherapy following vaccination. A relative low count of lymphocytes before and after vaccination was present in 11/19 patients indicating that these patients were immunocompromised. This study shows that HPV16 E7 peptide vaccination is feasible, even in a group of patients with terminal disease. This paves the way for vaccinating patients with less advanced disease, whose immune system is less compromised by progressive disease.
authors.affiliation: Department of Gynaecology, Leiden University Medical Centre, The Netherlands. w.j.vandriel@kgc.azl.nl
authors.forename: W J
authors.initials: WJ
authors.lastname: van Driel
authors.forename: M E
authors.initials: ME
authors.lastname: Ressing
authors.forename: G G
authors.initials: GG
authors.lastname: Kenter
authors.forename: R M
authors.initials: RM
authors.lastname: Brandt
authors.forename: E J
authors.initials: EJ
authors.lastname: Krul
authors.forename: A B
authors.initials: AB
authors.lastname: van Rossum
authors.forename: E
authors.initials: E
authors.lastname: Schuuring
authors.forename: R
authors.initials: R
authors.lastname: Offringa
authors.forename: T
authors.initials: T
authors.lastname: Bauknecht
authors.forename: A
authors.initials: A
authors.lastname: Tamm-Hermelink
authors.forename: P A
authors.initials: PA
authors.lastname: van Dam
authors.forename: G J
authors.initials: GJ
authors.lastname: Fleuren
authors.forename: W M
authors.initials: WM
authors.lastname: Kast
authors.forename: C J
authors.initials: CJ
authors.lastname: Melief
authors.forename: J B
authors.initials: JB
authors.lastname: Trimbos
mesh_terms: D000328:Adult; D000368:Aged; D019496:Cancer Vaccines / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008875:Middle Aged; D009856:Oncogene Proteins, Viral / Q000276:immunology*; D027383:Papillomaviridae / Q000276:immunology*; D050725:Papillomavirus E7 Proteins; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000821:virology; D014765:Viral Vaccines / Q000627:therapeutic use*
chemical_list: D019496:Cancer Vaccines; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D014765:Viral Vaccines; C059731:oncogene protein E7, Human papillomavirus type 16